However, even if compounding were banned, the global shortage is forecast to ease as manufacturing capacity catches up with demand and new, more powerful versions of the drug become available
The intricate interplay among body weight, stress, and the immune response to friend or foe
Patent intelligence tools, including those provided by DrugPatentWatch, now need to answer a different question: not just when does exclusivity expire, but what is the viable cost-plus entry price for this molecule, and how does that price compare to current protected pricing
This will come back up later in the episode, but Eli Lilly, although Insulin wasn't still is a huge part of the business, what they basically decided is to be a technology follower and license from all the innovation coming out of Novo and Nordisk, license that into their sales and distribution channels in the US
This launch features drugs made by the first five manufacturers to reach most-favored-nation (MFN) pricing deals with the Trump administration, including: AstraZeneca, Eli Lilly EMD Serono Novo Nordisk Pfizer Eli Lilly and Novo Nordisk have made their weight loss drugs Zepbound and Wegovy available through the TrumpRx platform